Logo
Login
$CRVS
$10.45 -$0.08 (0.76%) Close

Company Executives

$CRVS Management Team

Mr. Jeffrey Arcara

Senior Vice President

Chief Business Officer

Age 56
Compensation -
Sex Male

Dr. Richard Miller

Chairman of the Board

President

Chief Executive Officer

Age 74
Compensation $3.073M USD
Sex Male

Mr. Leiv Lea

Chief Financial Officer

Age 71
Compensation $1.614M USD
Sex Male

Dr. William Jones

Senior Vice President - Pharmaceutical Development

Age 60
Compensation $1.570M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 24, 2026
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
7.0 years
from year joined
CEO also chairs the board
Yes
Richard A. Miller, M.D.
Director Age On board Independent Committees Other public boards Pay Source
Richard A. Miller, M.D.
Board chair, CEO
 75 Not stated Not independent None stated None stated Paid as CEO
Linda S. Grais, M.D., J.D.
69 2019
7 years
 Independent None stated ICON plc Not stated
Andrew C. Chan, M.D., Ph.D.
Not stated Not stated Independent
Nominating and Corporate Governance Committee
None stated Not stated
Richard van den Broek
Not stated Not stated Independent None stated None stated Not stated
Ian T. Clark
Not stated Not stated Independent
Compensation Committee Nominating and Corporate Governance Committee
None stated Not stated
David S. Moore
Not stated Not stated Independent
Audit Committee Compensation Committee
None stated Not stated
Peter A. Thompson, M.D.
Not stated Not stated Independent
Nominating and Corporate Governance Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

4 disclosed in the proxy filed Apr 24, 2026
OrbiMed Advisors LLC
Peter A. Thompson, M.D., a member of our Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors LLC
$ 2,499,856

Purchase of pre-funded warrants and common warrants in the May 2024 registered direct offering

Open in proxy
Puissance Capital Management
Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management.
1,500,000

Purchase of shares and common warrants in the May 2024 registered direct offering

Open in proxy
Richard A. Miller, M.D.
Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board.
1,000,000

Purchase of shares and common warrants in the May 2024 registered direct offering

Open in proxy
William B. Jones, Ph.D.
William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development.
34,624

Purchase of shares and common warrants in the May 2024 registered direct offering

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans